FINWIRES · TerminalLIVE
FINWIRES

Medicenna Q2 Net Loss Flat at C$0.06 Per Share

By

Medicenna Therapeutics (MDNA.TO) said Friday its second-quarter loss of C$0.06 per share was unchanged from the prior-year period.

Analysts polled by FactSet had expected a net loss of C$0.06 per share.

The biotechnology company which is developing engineered versions of cytokines, which it calls "superkines", said enrolment in the monotherapy and combination expansion cohorts of the ABILITY-1 trial will be completed in the third quarter.

It plans to present updated MDNA11 clinical results in an oral presentation at a medical conference and to meet with the US Food and Drug Administration to discuss the potential for an expedited registrational development path for MDNA11.

Medicenna will also orally present new clinical data for its drug candidate bizaxofusp (formerly MDNA55), used to treat unresectable recurrent IDH-WT glioblastoma, a fatal form of brain cancer, at a medical conference, a statement said.

Medicenna shares were last seen up C$0.03 to C$0.43 on the Toronto Stock Exchange.

Price: $0.43, Change: $+0.03, Percent Change: +7.50%

Related Articles

Mining & Metals

Firm Capital Mortgage Investment Reports Lower Q2 Earnings, Net Income; Monthly Dividends Declared

Firm Capital Mortgage Investment (FC.TO) after trade Thursday reported second-quarter earnings per share of C$0.235, down from C$0.263 a year ago.Three analysts polled by FactSet on average expected C$0.25.Net income for the quarter ended June 30 fell to C$8.6 million from C$9.7 million a year earlier. The company said the decline was primarily due to a smaller average investment portfolio and lower average portfolio yields during the period.Three analysts polled by FactSet expected sales of C$14 million and net income of C$9 million.The company said its board declared a monthly cash dividend of C$0.078 per common share. It will be paid on Nov. 16 to shareholders of record as of Oct. 30, and on Dec. 15 to shareholders of record as of Nov. 30.

$FC.TO
Mining & Metals

Dynacor Group Q2 Earnings Miss FactSet Estimate Despite Higher Sales

Dynacor Group (DNG.TO) after market close on Thursday reported second-quarter earnings of $0.03 per share, compared with $0.08 per share in the prior-year period, missing the FactSet consensus of $0.13 per share.Net income for the quarter ended June 30 was $1.1 million, down from $3.5 million in the same period last year.The company recorded Q2 sales of $144.4 million, up from $79.7 million in the corresponding period of 2025 and above the FactSet consensus of $134.4 million.Dynacor said it is tracking its 2026 guidance, which calls for sales of $530 million to $580 million, net income of $22 million to $26 million and production of 125,000 to 135,000 gold equivalent ounces. The company also expects capital expenditures of $32.5 million to $39 million to support its 2026 growth plan and sustain existing operations.Its shares closed unchanged at C$6.61 on Toronto Stock Exchange on Thursday.

$DNG.TO
Mining & Metals

True North Commercial REIT Second-Quarter AFFO Climbs to C$0.49

True North Commercial REIT (TNT-UN.TO) said Thursday after trade that second quarter adjusted funds from unit rose to C$0.49 from C$0.42, in the prior year period.Revenue fell 0.9% to C$27.9 million year over year, due to a reduction in the REIT's Ottawa market occupancy as a result of a "strategically executed" early lease termination, a statement said.True North said its core portfolio occupancy at the end of the second quarter was 96% with a weighted average lease term of 4.2 years.True North units closed up C$0.08, to C$8.64 on the Toronto Stock Exchange.

$TNT-UN.TO